bluuebunny/crossref_metadata_2025_split huggingface dataset:
Design and validation of a bedside decision instrument to elicit a patient's preference concerning allogenic bone marrow transplantation in chronic myeloid leukemia
Authors: Sebban C. , Browman G. , Gafni A. , Norman G. , Levine M. , Assouline D. , Fiere D. 
Published: February 2007

AbstractThe objective of this study was to design and validate a bedside decision instrument to be used by patients with chronic myeloid leukemia and their physicians in deciding between the therapeutic alternatives of bone marrow transplantation and conservative management during the early phase of disease.A decision board was constructed containing detailed scenarios associated with the treatment alternatives, together with estimates of survival probabilities at various periods of followup. The instrument was tested on 42 healthy hospital personnel and validated by measuring the extent to which systematic alterations in the scenarios with respect to toxicities and survival probabilities produced predicted shifts in treatment preferences. A subgroup of respondents was randomized to receive information through the decision board alone or a shorter and less informative version of the instrument, followed by the decision board. The direction and strength of stated preferences were compared, together with satisfaction for these preferences.The direction and strength of preferences between bone marrow transplantation or conservative chemotherapy were influenced in a predictable way by changes in the toxicity and survival descriptions in the scenarios. Using the test‐retest method in 16 subjects, the stated preferences were found to be highly reliable (intraclass correlation coefficient, 0.87). The mean level of satisfaction with the stated preference, on a scale from not at all satisfied = 1 to very satisfied = 5, was higher for those exposed to the decision board (3.7, SD 1.06) compared with those presented with the short version (2.95, SD 0.67) (p < 0.01).The results demonstrate the feasibility and acceptability of the instrument in healthy individuals. The preferences elicited by the instrument appear to be reliable and valid according to prespecified constructs of the relation between the information provided and the preferences predicted. These results support further testing of this approach in actual patients. © 1995 Wiley‐Liss, Inc.
Myelodysplastic syndrome treatment with danazol and cis‐retinoic acid
Authors: Letendre Louis , Levitt Ralph , Pierre Robert V. , Schroeder Georgene , Krook James A. , Mailliard James E. , Morton Roscoe F. , Tschetter Loren K. 
Published: February 2007

AbstractWe prospectively treated 46 patients with favorable myelodysplastic syndrome classified as refractory anemia (RA), refractory cytopenia (RC), or refractory anemia with ringed sideroblasts (RARS). These patients received one of two schedules of 13‐Cis‐Retinoic Acid (low dose 80 mg daily for 6 months vs. high dose 200 mg po daily for 3 months), or Danazol (800 mg po daily for 3 months), and were crossed over to the alternative drug in the absence of response or at progression.Using strict criteria of response we found little objective evidence of activity for either compound. Only two minor responses were seen among 22 patients treated with low dose 13‐CRA, 1 response among 20 cases that received high dose 13‐CRA, and 1 partial response and 1 minor response to Danazol among 34 cases.Neither 13‐Cis‐Retinoic Acid nor Danazol appear active enough in patients with favorable myelodysplastic syndrome to justify their use. © 1995 Wiley‐Liss, Inc.
Discrimination of Hb D Los Angeles (B121 Glu‐Gln) and Hb Beograd (B121 Glu‐Val) by Dual Restriction Enzyme Analysis
Authors: Akar N. , Özden A. , Akar E. , Cin S. , Arcasoy A. 
Published: February 2007

AbstractHb D Los Angeles (B121 Glu‐Gln) and Hb Beograd (B121 Glu‐Val) can be identified by different techniques. Here we describe a dual restriction enzyme digestion protocol (EcoR I G AATTC) and Tsp509 I (AATT) for the discrimination of these variants.
Expression pattern of CD45 RA/RO isoformic antigens in T‐lineage neoplasms
Authors: Kawano Seiji , Tatsumi Eiji , Yoneda Noriko , Tani Akemi , Nakamura Fumihiko 
Published: February 2007

AbstractThe expression of CD45 RA/RO antigen was investigated in neoplasms including cases expressing CD7 antigen as the sole pan‐T antigen (n = 8), T‐lineage acute lymphoblastic leukemia (ALL)/lymphoblastic lymphoma (LBL) at various stages of differentiation (n = 32), peripheral stage T‐lineage leukemia (n = 10) and adult T‐cell leukemia (ATL) (n = 14). The p56Ick gene expression was also investigated in selected cases.The expression pattern of CD45 RA/RO antigen was defined as of RA, mixed, or RO type. All but one CD7+ CD5− CD2− case were of the RA type. The CD7+ CD5+ CD2− prothy‐mic stage included seven RA and one mixed type cases. One CD7+ CD5− CD2+ case was of the RA type, but the other was of the RO type. The CD7+ CD5+ CD2+ prothymic stage included three RA and four mixed type cases. All seven CD3− CD4+ CD8+ (double‐positive) thymic cases were of the RO type. The CD3+ CD4+ CD8+ (triple‐positive) stage included two RO and three mixed‐type cases. One CD3+ CD4+ CD8− late thymic case was of the mixed type. The peripheral stage cases included five RA, three RO, and two mixed type cases. All ATL cases were of the RO type. The expression of p56Ick gene in the prothymic stage was less marked than that in the thymic stage.On the basis of these results, the following sequence of pattern of the CD45 RA/RO antigen expression along with T‐lineage differentiation was reconstructed: prothymic stage [RA and mixed type] → double‐positive thymic stage [RO type] → triple‐positive thymic stage [RO and mixed type] → peripheral stage [RA, mixed, and RO type]. While one RO‐type CD7+ CD5− CD2− and one RO‐type CD7+ CD5− CD2+ cases were not in accord with this sequence, the pattern of CD45 RA/RO antigen expression in most of T‐lineage neoplasms could be determined by the respective stage of differentiation. The poor expression of the p56Ick gene by the prothymic blasts compared with the thymic blasts may be related to the expression pattern of the CD45 RA/RO molecules, which exhibits phosphatase activity. The consistent RO‐type expression in the ATL cases may reflect the activated status of the neoplastic T cells due to the presence of the HTLV‐I gene. Alternatively, the target cells for HTLV‐I‐induced neoplastic transformation may possibly be of the RO type. © 1995 Willey‐Liss, Inc.
Application of interphase cytogenetics to monitor bone marrow transplants
Authors: Vrazas Vickie , Ooms Lisa M. , Rudduck Christina , Szer Jeffrey , Campbell Lynda J. , Garson O. Margaret 
Published: February 2007

AbstractChromosomal in situ hybridization (ISH) has extended the scope of cytogenetic analysis to nondividing cells by the use of chromosome‐specific probes detected by nonisotopic techniques. This provides a rapid and sensitive method for identifying chromosomes in interphase cells, and is useful in gauging engraftment following bone marrow transplantation, particularly when the number of cells obtained is minimal. We have performed ISH using a Y‐heterochromatin‐specific probe to monitor patients with malignant hematological disease who have received a sex‐mismatched transplant. The results have been compared with those obtained from concurrently performed standard cytogenetic analysis. Host cells were detected by interphase cytogenetics in all patients posttransplant, at times varying from 28‐1,825 days, whereas routine analysis detected host cells in only 4 patients, 3 of whom were found to be in relapse. The significance of the persistence of host cells is unknown, but it does not appear to indicate impending relapse. © 1995 Wiley‐Liss, Inc.
Essential thrombocythemia: A retrospective analysis of 39 cases
Authors: Kwong Y. L. , Liang R. H. S. , Chiu E. K. W. , Lie A. K. W. , Chan L. C. , Todd D. , Chan T. K. 
Published: February 2007

AbstractThirty‐nine Chinese patients presenting as essential thrombocythemia (ET) were analyzed retrospectively. The median age at presentation was 69 years and the M:F ratio was 1.35:1. At diagnosis, 33 cases (84%) were asymptomatic and the diagnosis was made incidentally, while 3 cases (8%) presented with small vessel, and 2 cases (5%) with large vessel, thrombosis. One patient (3%) presented with minor bleeding. The platelet count ranged from 0.9‐34 × 1012/1. Of 12 karyotypes done, 2 cases were abnormal, both showing the Philadelphia (Ph) chromosome. First‐line therapy was radiophosphorus (32P) in 3 cases, melphaian in 20 cases, and hydroxyurea in 12 cases; 4 cases did not receive specific therapy. During the follow‐up (mean = 4 years), no thrombotic or bleeding episodes were observed. One patient with the Ph chromosome underwent blastic transformation. These results indicate that bleeding and thrombosis occur significantly less in Chinese patients than in Western patients. The Ph chromosome appears to be a bad prognostic indicator. Because of the very low incidence of complications and good prognosis, the authors believe that cytoreductive therapy is best achieved by the use of hydroxyurea instead of alkylating agents or radiophorphours, as the latter agents are potentially leukemogenic. © 1995 Wiley‐Liss, Inc.
Myocardial infarction and thalassemia trait: An example of heterozygote advantage
Authors: Wang Cheng‐Hsu , Schilling Robert F. 
Published: February 2007

AbstractThis study was designed to test the hypothesis that thalassemia trait diminishes the likelihood of myocardial infarction. If the hypothesis is true the prevalence of thalassemia trait should be less in myocardial infarct patients than in a control population. Blood counts and blood chemistry data from 500 men in Taiwan with a discharge diagnosis of myocardial infarction were recorded, and similar data were gathered on 500 men admitted to the same hospital for a routine check‐up. Thalassemia trait was diagnosed via a discriminant function applied to the red blood cell count and indices. The study was done in a large modern hospital in Taipei; 14 of the 500 infarct patients and 33 of the 500 non‐infarct subjects had thalassemia trait as defined here. The prevalence of thalassemia trait in myocardial infarct patients is significantly less than in the control subjects. This case control study supports the hypothesis that thalassemia trait lessens the risk of myocardial infarction. © 193s Wiley‐Liss, Inc.
Inhibitory activity of anti‐β2‐glycoprotein I antibody on factor va degradation by activated‐protein C and its cofactor protein S
Authors: Matsuda Juzo , Gohchi Kengo , Kawasugi Kazuo , Gotoh Moritaka , Saitoh Noriko , Tsukamoto Miyo 
Published: February 2007

AbstractWe investigated the influence of anti‐β2‐glycoprotein I (aGPI), which recently has come to be regarded as anti‐cardiolipin antibody (aCL) itself, on factor Va (FVa) degradation by activated protein C/protein S system. We found that aGPI had an inhibitory effect on FVa degradation with β2‐glycoprotein I‐dependency, thus suggesting aGPI/aCL is a highly possible factor as the pathogenesis of thrombosis observed in aGPI/aCL‐positive patients. © 1995 Wiley‐Liss, Inc.
Treatment of aggressive Non‐Hodgkin's lymphoma in the elderly
Authors: Novitzky Nicolas , King Helen S. , Johnson Carol , Jacobs Peter 
Published: February 2007

AbstractA nonanthracycline‐containing chemotherapeutic combination for the treatment of intermediate and high‐grade non‐Hodgkin's lymphoma was evaluated. Thirty‐four consecutive and previously untreated patients, with a median age of 75 (range 54‐86) years, with aggressive lymphoma, received daily etoposide (60 mg/m2 intravenous infusion [IVI]), cytosine arabinoside (50 mg/m2 subcutaneously), and methylprednisolone (60 mg/m2 IVI) on each of 5 consecutive days. Individuals with limited disease (stages I and II) (n = 9) received six, 3‐day cycles of the same therapy and involved field radiation (36 Gy in 20 fractions) between the third and fourth courses. Patients with disseminated lymphoma (n = 25) received 10 cycles over 8 months of the same combination, with the addition of methotrexate (200 mg/m2 on days 8 and 15), followed by leucovorin rescue (10 mg/m2 orally every 6 hr for 8 doses).Of the 34 patients, 44% entered complete remission (CR), and 7 died before completing the first cycle of chemotherapy. Fifty‐six percent of the patients with limited disease and 40% with disseminated lymphoma (P > 0.05) achieved CR. For all patients, median survival was 14 months (range 3 days‐>54 months), this being 12 and 15 months, respectively. For the entire population of responding patients, median survival has not been reached at a median follow‐up of 39 months, while the median CR duration is 21 months. Ten of the 15 responders are alive in unmaintained CR at a median of 41 (range 30‐54) months. Myelotoxicity was the major side effect, leading to adjustments in dose and schedule in two‐thirds of the patients, although treatment changes did not affect outcome. Of the 15 deaths that occurred in this trial, in 53.3% it was unrelated to lymphoma or its therapy. Four patients that had achieved CR died of cardiovascular events (n = 2) or of progressive second malignancies (n = 2).It is concluded that cytosine arabinoside in combination regimens is effective in selected patients; this is particularly relevant in the elderly. © 1995 Wiley‐Liss, Inc.
Large molecule fraction of plasma separated with polyethylene glycol in treatment of chronic relapsing thrombotic thrombocytopenic purpura
Authors: Fujita Masahiro , Ito Kazuhiko , Koyama Tetsuji , Shino Kazuko , Norioka Mihoko , Kashii Saburo , Kawamoto Hiroshi , Monden Sumie , Kakishita Eizo , Okuma Minoru 
Published: February 2007

AbstractPlasma exchange and plasma infusion are effective in the treatment of patients with thrombotic thrombocytopenic purpura (TTP). It has been proposed that some component in normal plasma may be deficient in TTP patients. In this experiment normal plasma was fractionated and an effective fraction for the treatment of TTP was sought. Plasma was fractionated with 5% polyethylene glycol and a large molecule fraction was obtained which was composed mainly of proteins and lipoproteins with molecules larger than that of IgG. The fraction was dissolved in physiological saline and infused in two patients with chronic relapsing TTP who had been successfully treated periodically with plasma infusion. Peripheral platelet counts and serum LDH levels were measured, and the efficacy of the treatment was assessed. Infusion of the large molecule fraction elevated platelet counts and lowered the LDH level. However, the efficacy of the large molecule fraction was 25 to 50% that of plasma. Components in the fraction may have been inactivated partially during preparation. We propose that the large molecule fraction contains factors which are effective in some patients with TTP. © 1995 Wiley‐Liss, inc.
Familial myelodysplastic syndrome with onset late in life
Authors: Marsden Katherine , Challis David , Kimber Roger 
Published: February 2007

AbstractA family is described in which three, and possibly four members, namely, the propositus, two paternal uncles, and possibly his paternal grandfather, developed a myelodysplastic syndrome (MDS) after the age of 60 years. This late onset resembles sporadic cases which are commoner in older age, rather than the previously reported familial cases most of whom have been children or young adults. The three affected members had megaloblastoid bone marrows with an increased proportion of bone marrow blasts and developed progressive bone marrow failure without leukemic transformation. The propositus showed a dramatic but temporary response to GM‐CSF therapy but eventually became unresponsive with a marked increase in bone marrow reticulin and reduction in hemopoietic elements. Affected members had no recognisable bone marrow cytogenetic abnormality but the pattern of inheritance and similarity in clinical features suggest an inherited genetic defect which predisposes to the development of MDS. © 1995 Wiley‐Liss, Inc.
Hematological features of patients with myelodysplastic syndromes associated with a chromosome 5q deletion
Authors: Lewis S. , Oscier D. , Boultwood J. , Ross F. , Fitchett M. , Rack K. , Abrahamson G. , Buckle V. , Wainscoat J. S. 
Published: February 2007

AbstractThe hematological and clinical features of 26 patients with myelodysplasia and a chromosome 5q deletion in the bone marrow are presented. We have examined the relationship of French‐American‐British Co‐operative Group (FAB) 1982 classification and bone marrow karyotype at diagnosis with patient outcome and the presence or absence of the classical features of the 5q‐ syndrome. Those patients classified as refractory anemia (RA) with no additional karyotypic abnormalities have the typical features of the 5q‐ syndrome and a good prognosis. None of the patients in this group transformed to acute leukemia during the period of follow‐up. Patients with either refractory anemia and excess blasts (RAEB) or additional karyotypic abnormalities show many of the hematologic features of the 5q‐ syndrome but do not share the good prognosis. We conclude that the 5q‐ syndrome may be best defined as primary MDS of the FAB type RA with a 5q deletion as the sole karyotypic abnormality. This simple definition will distinguish patients with a good prognosis and all the classical features of the 5q‐ syndrome.
T‐Cell large granular lymphocytic leukemia following orthotopic liver transplantation
Authors: Feher O. , Barilla D. , Locker J. , Oliveri D. , Melhem M. , Winkelstein A. 
Published: February 2007

AbstractAggressive T‐cell neoplasms are an infrequent complication of allogeneic organ and bone marrow transplantation. To date, chronic T‐cell lymphoproliferative malignancies have not been described. The present case documents the occurrence of a T‐cell large granular lymphocytic leukemia (T‐LGL) in a patient following orthotopic liver transplantation. Genotype studies showed a clonal T‐cell receptor α‐chain gene rearrangement. A unique feature was the detection of a specific chromosomal deletion at 1p32 involving the tal‐1 gene, an abnormality previously described only in aggressive T‐cell neoplasms. © 1995 Wiley‐Liss, Inc.
Hypertriglyceridemia may be severe in CML patients treated with interferon‐α
Authors: Peñarrubia María Jesús , Steegmann Juan Luis , Lavilla Esperanza , Casado Felipe , Requena María José , Picó Mónica , Arranz Reyes , Fernández‐Rañada José María 
Published: February 2007

AbstractWe analyzed serum triglyceride (TG) levels in 22 chronic myeloid leukemia (CML) patients treated with interferon‐α (IFN‐α). Hypertriglyceridemia was present in one‐half of patients at diagnosis, and IFN‐α treatment was associated with a further increase in 90% of the total group of patients. This increase was maximal during the first months of therapy. Four patients (18%) reached levels higher than 1,000 mg/dl. This is the first report describing this secondary effect in CML patients treated with IFN‐α. © 1995 Wiley‐Liss, Inc.
Isobutyramide therapy in patients with sickle cell anemia
Authors: Saleh A. W. , Van Goethem A. , Jansen R. , Velvis H. J. R. , Gu L.‐H. , Huisman T. H. J. 
Published: February 2007

AbstractWe have administered Isobutyramide as a suspension over a period of 3 months, from a starting dose of 50 mg/kg/day up to 150 mg/kg/day, to four adult sickle cell (SS) anemia patients. The maximum dose was maintained for 3 weeks. The blood counts remained stable and the Hb F levels decreased slightly. The Gγ levels increased at the end of the trial, suggesting activation of the Gγ gene at the highest dose of Isobutyramide. Three patients showed a stable rate of hemolysis, while in one patient, an increase of lactate dehydrogenase occurred. None of the patients experienced pain crisis or organ‐specific crisis, but all four complained about mild epigastric burning and a bitter taste. After the first month of treatment one patient complained about intolerable epigastric discomfort which was relieved by Omeprazole. Another patient complained about increasing dyspepsia in the 12th week leading to the termination of the trial. Oral Isobutyramide administration does not qualify as an effective treatment of SS patients. © 1995 Wiley‐Liss, Inc.
Endothelial cells injured by oxidized low density lipoprotein
Authors: Zhao B. , Zhang Y. , Liu B. , Nawroth P. , Dierichs R. 
Published: February 2007

AbstractCultured endothelial cells from bovine aorta were exposed to oxidized low density lipoprotein and examined by electron microscopy. The endothelial cells contracted slightly and the intercellular junctions became unclear. Some osmiophilic material increased in the cytoplasm. The oxidized low density lipoprotein appears to injure endothelial cells and thereby plays a causative role in atherogenesis and thrombogenesis. © 1995 Wiley‐Liss, Inc.
Abnormal γIFN and αTNF secretion in purified CD2+ cells from autoimmune thrombocytopenic purpura (ATP) patients: Their implication in the clinical course of the disease
Authors: Garcia‐Suarez J. , Prieto A. , Reyes E. , Manzano L. , Arribalzaga K. , Alvarez‐Mon M. 
Published: February 2007

AbstractGamma inferferon (γIFN), alpha tumor necrosis factor (αTNF), and interleukin 6 (IL‐60) are cytomines produced by a wide variety of cells, incuding T lymphocys and NK cells. These cytokines affect B‐cell proliferation and differentiation into immunoglobulin seceting cells. In addition, γIFN and αTNF also enhance the function of macrophagesm, upregulating the expresson of their igG receptors. Abonormalities in the production of these cytokines may be involved in the clinical course of autoimmune thrombocytopenic purpura (ATP). This paper describes the production of these cytokines in PHA‐stimulated peripheral blood CCD2+ cells from ATP patients.Both γIFN and αTNF were significantly increased in PHA‐stimulated CD2+ cells from therapy‐dependent ATP patients (platelet counts <50,000/μl), as compared to ATP patients with stable disease (sustained platelet counts >50,000/μl without need treatment) (P < 0.05). No significant differences were found in γlFN production by PHA‐stimulated CD2+ cells between therapy‐dependent ATP patients and healthy controls (P < 0.05). However, the production of αTNF by PHA‐stimulated CD2+ cells from therapy‐dependent ATP patients was significantly higher compared to that found in healthy controls (P < 0.05). There were no significant differences in IL‐6 production by PHA‐stimulated CD2+ cells from ATP patients and healthy controls (P < 0.05).These findings demonstrate abnormal γlFN and αTNF secretion in purified CD2 cells from ATP patients. The clinical severity of the disease is associated with the altered secretion of these lymphokines by CD2 cells. © 1995 Wiley‐Liss, Inc.